Literature DB >> 16007713

C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions.

Ian Cumpstey1, Anders Sundin, Hakon Leffler, Ulf J Nilsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16007713     DOI： 10.1002/anie.200500627

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  26 in total

1.  The inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship.

Authors:  Xiaoge Gao; Yuan Zhi; Lin Sun; Xiaoxia Peng; Tao Zhang; Huiting Xue; Guihua Tai; Yifa Zhou
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

2.  A minimalistic approach to develop new anti-apicomplexa polyamines analogs.

Authors:  Esteban A Panozzo-Zénere; Exequiel O J Porta; Gustavo Arrizabalaga; Lucía Fargnoli; Shabana I Khan; Babu L Tekwani; Guillermo R Labadie
Journal:  Eur J Med Chem       Date:  2017-12-02       Impact factor: 6.514

3.  Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Authors:  Ruud P M Dings; Nigam Kumar; Michelle C Miller; Melissa Loren; Huzaifa Rangwala; Thomas R Hoye; Kevin H Mayo
Journal:  J Pharmacol Exp Ther       Date:  2012-12-11       Impact factor: 4.030

Review 4.  The roles of Galectin-3 in autoimmunity and tumor progression.

Authors:  Gordana Radosavljevic; Vladislav Volarevic; Ivan Jovanovic; Marija Milovanovic; Nada Pejnovic; Nebojsa Arsenijevic; Daniel K Hsu; Miodrag L Lukic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

5.  Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.

Authors:  Olga V Glinskii; Sudha Sud; Valeri V Mossine; Thomas P Mawhinney; Douglas C Anthony; Gennadi V Glinsky; Kenneth J Pienta; Vladislav V Glinsky
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

Review 6.  Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.

Authors:  Vanessa Leiria Campo; Marcelo Fiori Marchiori; Lílian Cataldi Rodrigues; Marcelo Dias-Baruffi
Journal:  Glycoconj J       Date:  2016-08-15       Impact factor: 2.916

7.  Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.

Authors:  Neil C Henderson; Alison C Mackinnon; Sarah L Farnworth; Tiina Kipari; Christopher Haslett; John P Iredale; Fu-Tong Liu; Jeremy Hughes; Tariq Sethi
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

8.  Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3.

Authors:  Carl Diehl; Olof Engström; Tamara Delaine; Maria Håkansson; Samuel Genheden; Kristofer Modig; Hakon Leffler; Ulf Ryde; Ulf J Nilsson; Mikael Akke
Journal:  J Am Chem Soc       Date:  2010-10-20       Impact factor: 15.419

9.  Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Authors:  Ruud P M Dings; Michelle C Miller; Irina Nesmelova; Lucile Astorgues-Xerri; Nigam Kumar; Maria Serova; Xuimei Chen; Eric Raymond; Thomas R Hoye; Kevin H Mayo
Journal:  J Med Chem       Date:  2012-05-30       Impact factor: 7.446

10.  Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.

Authors:  Koichi Ito; Stacy A Scott; Samuel Cutler; Lan-Feng Dong; Jiri Neuzil; Helen Blanchard; Stephen J Ralph
Journal:  Angiogenesis       Date:  2011-04-27       Impact factor: 9.596
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.